(Q28217877)

cost-effectiveness analysis

inferred from title

1 reference

Oscar H Franco

1

0 references

author name string

Arno J der Kinderen

2

0 references

Chris De Laet

3

0 references

Anna Peeters

4

0 references

Luc Bonneux

International Journal of Technology Assessment in Health Care

5

0 references

language of work or name

English

0 references

publication date

2007

0 references

published in

0 references

volume

23

0 references

issue

1

0 references

page(s)

71-9

0 references

cites work

Coronary heart disease prevention: insights from modelling incremental cost effectiveness

1 reference

https://api.crossref.org/works/10.1017/S0266462307051598

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1017/S0266462307051598

A strategy to reduce cardiovascular disease by more than 80%

21 April 2017

1 reference

https://api.crossref.org/works/10.1017/S0266462307051598

Risk factor thresholds: their existence under scrutiny

21 April 2017

1 reference

https://api.crossref.org/works/10.1017/S0266462307051598

Cost effectiveness of ramipril treatment for cardiovascular risk reduction

21 April 2017

1 reference

https://api.crossref.org/works/10.1017/S0266462307051598

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 April 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 April 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Cost effectiveness of statins in coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Cardiovascular disease risk profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Clinical context: current concepts of coronary heart disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Determinants of disease and disability in the elderly: The Rotterdam elderly study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Economics of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Discounting costs and effects: a reconsideration

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Nicotine replacement therapy for smoking cessation

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

An investigation of coronary heart disease in families. The Framingham offspring study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Antidepressants for smoking cessation

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021

Epidemiological approaches to heart disease: the Framingham Study

1 reference

https://api.crossref.org/works/10.1017%2FS0266462307051598

7 January 2021